These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
501 related articles for article (PubMed ID: 32336675)
1. Improved Outcomes of All-trans-retinoic Acid and Arsenic Trioxide Plus Idarubicin as a Frontline Treatment in Adult Patients With Acute Promyelocytic Leukemia. Yang S; Ma R; Yuan X; Jiang L; Shi J; Yang J; Lei P; Zang Y; Chen X; Zhang Y; Liu Z; Guo J; Zhang L; Zhu X; Zhu Z Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e382-e391. PubMed ID: 32336675 [TBL] [Abstract][Full Text] [Related]
2. All-trans Retinoic Acid, Arsenic Trioxide, and Anthracycline-based Chemotherapy Improves Outcome in Newly Diagnosed Acute Promyelocytic Leukemia Regardless of FLT3-ITD Mutation Status. Xu LW; Su YZ; Tao HF Curr Med Sci; 2021 Jun; 41(3):491-497. PubMed ID: 34169421 [TBL] [Abstract][Full Text] [Related]
3. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Iland HJ; Bradstock K; Supple SG; Catalano A; Collins M; Hertzberg M; Browett P; Grigg A; Firkin F; Hugman A; Reynolds J; Di Iulio J; Tiley C; Taylor K; Filshie R; Seldon M; Taper J; Szer J; Moore J; Bashford J; Seymour JF; Blood; 2012 Aug; 120(8):1570-80; quiz 1752. PubMed ID: 22715121 [TBL] [Abstract][Full Text] [Related]
4. Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial. Zhang L; Zou Y; Chen Y; Guo Y; Yang W; Chen X; Wang S; Liu X; Ruan M; Zhang J; Liu T; Liu F; Qi B; An W; Ren Y; Chang L; Zhu X BMC Cancer; 2018 Apr; 18(1):374. PubMed ID: 29615003 [TBL] [Abstract][Full Text] [Related]
5. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial. Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214 [TBL] [Abstract][Full Text] [Related]
6. Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group. Adès L; Thomas X; Bresler AG; Raffoux E; Spertini O; Vey N; Marchand T; Récher C; Pigneux A; Girault S; Deconinck E; Gardin C; Tournilhac O; Lambert JF; Chevallier P; de Botton S; Lejeune J; Dombret H; Chevret S; Fenaux P Haematologica; 2018 Dec; 103(12):2033-2039. PubMed ID: 30026341 [TBL] [Abstract][Full Text] [Related]
7. Outcome of Patients With Relapsed Acute Promyelocytic Leukemia. Sasaki K; Ravandi F; Kadia T; DiNardo CD; Yilmaz M; Short N; Jabbour E; Patel KP; Loghavi S; Pierce S; Borthakur G; Kantarjian H Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):375-381. PubMed ID: 38431521 [TBL] [Abstract][Full Text] [Related]
8. Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631. Kutny MA; Alonzo TA; Gerbing RB; Wang YC; Raimondi SC; Hirsch BA; Fu CH; Meshinchi S; Gamis AS; Feusner JH; Gregory JJ J Clin Oncol; 2017 Sep; 35(26):3021-3029. PubMed ID: 28767288 [TBL] [Abstract][Full Text] [Related]
9. Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report From the Children's Oncology Group AAML1331 Trial. Kutny MA; Alonzo TA; Abla O; Rajpurkar M; Gerbing RB; Wang YC; Hirsch BA; Raimondi S; Kahwash S; Hardy KK; Hardy S; Meshinchi S; Gamis AS; Kolb EA; Feusner JH; Gregory J JAMA Oncol; 2022 Jan; 8(1):79-87. PubMed ID: 34762093 [TBL] [Abstract][Full Text] [Related]
10. [Efficacy of Idarubicin-Based Stratified Therapy for Acute Promyelocytic Leukemia]. Guan W; Li WJ; Yang L; Jing Y; Yu L Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):353-357. PubMed ID: 28446274 [TBL] [Abstract][Full Text] [Related]
11. [Effect of triple-induction regimen including all-trans retinoic acid, arsenic trioxide plus anthracyclines for adults with non-high-risk acute promyelocytic leukemia]. Ma RJ; Yuan XL; Jiang L; Yang SW; Yang J; Wang Z; Zhang P; Zhang L; Shang BJ; Cheng LN; Zhang Y; Zhu ZM Zhonghua Yi Xue Za Zhi; 2021 Aug; 101(30):2387-2391. PubMed ID: 34404132 [No Abstract] [Full Text] [Related]
12. [Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis]. Xu SN; Chen JP; Liu JP; Xia Y Zhong Xi Yi Jie He Xue Bao; 2009 Nov; 7(11):1024-34. PubMed ID: 19912733 [TBL] [Abstract][Full Text] [Related]
13. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial. Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593 [TBL] [Abstract][Full Text] [Related]
14. Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA. Ghavamzadeh A; Jalili M; Rostami S; Yaghmaie M; Aliabadi LS; Mousavi SA; Vaezi M; Fumani HK; Jahani M; Alimoghaddam K Leuk Res; 2018 Mar; 66():85-88. PubMed ID: 29407588 [TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia. Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J Hematol Oncol; 2014 Mar; 32(1):40-6. PubMed ID: 23963734 [TBL] [Abstract][Full Text] [Related]
16. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D; Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238 [TBL] [Abstract][Full Text] [Related]
17. Oral arsenic trioxide, all-trans retinoic acid, and ascorbic acid maintenance after first complete remission in acute promyelocytic leukemia: Long-term results and unique prognostic indicators. Gill HS; Yim R; Kumana CR; Tse E; Kwong YL Cancer; 2020 Jul; 126(14):3244-3254. PubMed ID: 32365228 [TBL] [Abstract][Full Text] [Related]
18. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. Lo-Coco F; Avvisati G; Vignetti M; Thiede C; Orlando SM; Iacobelli S; Ferrara F; Fazi P; Cicconi L; Di Bona E; Specchia G; Sica S; Divona M; Levis A; Fiedler W; Cerqui E; Breccia M; Fioritoni G; Salih HR; Cazzola M; Melillo L; Carella AM; Brandts CH; Morra E; von Lilienfeld-Toal M; Hertenstein B; Wattad M; Lübbert M; Hänel M; Schmitz N; Link H; Kropp MG; Rambaldi A; La Nasa G; Luppi M; Ciceri F; Finizio O; Venditti A; Fabbiano F; Döhner K; Sauer M; Ganser A; Amadori S; Mandelli F; Döhner H; Ehninger G; Schlenk RF; Platzbecker U; ; ; N Engl J Med; 2013 Jul; 369(2):111-21. PubMed ID: 23841729 [TBL] [Abstract][Full Text] [Related]